[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @3primeAnalytica 3PrimeAnalytica 3PrimeAnalytica posts on X about $beam, $ntla, $crsp, $edit the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1372950951175278595/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +492,918% - X Year XXXXXXX +4,635% ### Mentions: X [#](/creator/twitter::1372950951175278595/posts_active)  - X Week XX -XX% - X Month XX -XXXX% - X Months XXX +16,400% - X Year XXX +1,560% ### Followers: XXXXX [#](/creator/twitter::1372950951175278595/followers)  - X Week XXXXX +0.71% - X Month XXXXX +9.90% - X Months XXXXX +37% - X Year XXXXX +37% ### CreatorRank: undefined [#](/creator/twitter::1372950951175278595/influencer_rank)  ### Social Influence [#](/creator/twitter::1372950951175278595/influence) --- **Social category influence** [cryptocurrencies](/list/cryptocurrencies) XXXXX% [finance](/list/finance) XXXXX% [stocks](/list/stocks) XXXX% [travel destinations](/list/travel-destinations) XXXX% [currencies](/list/currencies) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [$beam](/topic/$beam) #65, [$ntla](/topic/$ntla) #37, [$crsp](/topic/$crsp) #30, [$edit](/topic/$edit) 8.33%, [$sana](/topic/$sana) 5.56%, [$prme](/topic/$prme) 5.56%, [$crbu](/topic/$crbu) 5.56%, [london](/topic/london) 2.78%, [$rgnx](/topic/$rgnx) 2.78%, [stocks](/topic/stocks) XXXX% **Top accounts mentioned or mentioned by** [@geneinvesting](/creator/undefined) [@tohjah7809](/creator/undefined) [@crisprtx](/creator/undefined) [@vegan1](/creator/undefined) [@biotech2k1](/creator/undefined) [@jawnzilla](/creator/undefined) [@rolandoamoreno](/creator/undefined) [@vega_n1](/creator/undefined) [@beamtx](/creator/undefined) [@astrazeneca](/creator/undefined) [@arkkdaily](/creator/undefined) [@matthughes13](/creator/undefined) [@thechartlife](/creator/undefined) [@rainmaker1973](/creator/undefined) [@primemedicine](/creator/undefined) [@intelliatx](/creator/undefined) [@oliverventure](/creator/undefined) [@neo8634](/creator/undefined) **Top assets mentioned** [BEAM (BEAM)](/topic/$beam) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [GSK plc (GSK)](/topic/$gsk) [Scholar Rock Holding Corporation Common Stock (SRRK)](/topic/$srrk) [AstraZeneca PLC (AZN)](/topic/$azn) ### Top Social Posts [#](/creator/twitter::1372950951175278595/posts) --- Top posts by engagements in the last XX hours "@TohJah7809 😁 green tea for the win matcha's so overpriced in London" [X Link](https://x.com/3primeAnalytica/status/1972177642066784677) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-28T05:52Z 1270 followers, XX engagements "Overnight looking good so far 👍🏼only bought a tiny bit of $BEAM last Friday though" [X Link](https://x.com/3primeAnalytica/status/1977532290528842215) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-13T00:30Z 1270 followers, 1763 engagements "FDA slapped Regenxbio with a 3-month delay on RGX-121 for Hunter syndrome - 'more data' is the favourite excuse 🙄. FDA delays continue to pile up = biotech dreams crushed again. $RGNX #FDAFail #Biotech #GeneTherapy 🔥" [X Link](https://x.com/3primeAnalytica/status/1958119699918594469) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-08-20T10:51Z 1272 followers, XXX engagements "after all these years 🥶 still being up on $NTLA $BEAM $CRSP after broad market jitters/liquidations I'm reading about this a.m. hits different" [X Link](https://x.com/3primeAnalytica/status/1977044203159929304) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-11T16:10Z 1272 followers, 1249 engagements ".you really never know in this space tbh might start talking up next-gen editors too.i actually (and amusingly) mentioned this before crsp even mentioned SyNTase.it's been a while since the so called "first gens" have talked about these programs.btw wen $NTLA gene/dna writing tech from Rewrite Tx" [X Link](https://x.com/3primeAnalytica/status/1977431195299287516) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-12T17:48Z 1272 followers, XXX engagements "Here's your Morning CRISPR Brief ☕☀ Recap: gene editing stocks dipped 3-9% on Oct. 10th amid broader market weakness but fundamentals remain intact $CRSP -XXXX% $SANA -XXXX% $NTLA -XXXX% $BEAM -XXXX% $EDIT -XXXX% $PRME -XXXX% $CRBU -9.45%. Big Pharmas interest in CRISPR is heating up again 🔥 as evidenced by several partnerships and deals just last week. The unveiling of a next-gen platform like SyNTase and good poc data reflects steady momentum in the gene editing sector. Some highlights from last week: 1) Non-dilutive win for @BeamTx: $BMY acquired Orbital Therapeutics BEAM's RNA" [X Link](https://x.com/3primeAnalytica/status/1977725387820954040) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-13T13:17Z 1272 followers, 2933 engagements "$WVE released positive interim results for its RNA-editing therapy WVE-006 primarily developed under a partnership with $GSK which holds the global license and will assume full responsibility post-trial. The data indicate comparable total alpha-1 antitrypsin (AAT) levels to those reported in $BEAM's - XXX program with both achieving approximately 1112 M. However BEAM-302 demonstrates higher relative production of functional M-AAT (91% of total AAT) and a greater reduction in pathogenic Z-AAT (79%) compared to WVE-006 (64% M-AAT and XX% Z-AAT reduction). Waves data does seem to validate" [X Link](https://x.com/3primeAnalytica/status/1963235994800365826) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-03T13:41Z 1270 followers, 1400 engagements "$REGN's Chris Fenimore (CFO) and Ryan Crowe (SVP IR) participated in a fireside chat at Bernstein yesterday. 📈💊 Stock has declined XX% YTD. I think one of the cheapest underappreciated biopharma LT opptys out there. Comments on $SRRK CRL their own CRL Dupixent Eylea onco pipelline Complement & obesity plays. 📍On EYLEA HD Performance and Headwinds: - Strong sequential demand growth observed: X% in Q1 and XX% in Q2 driven by effective commercial execution and education efforts. - Offering enhanced dosing flex and durability compared to EYLEA 2mg. - Ongoing challenges: securing approvals for" [X Link](https://x.com/3primeAnalytica/status/1971230672497820074) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-09-25T15:09Z 1272 followers, 2732 engagements "Here's your Morning CRISPR Brief ☕☀ Recap: $PRME led gains +19.32% followed by $CRSP +10% $EDIT +9.58% $NTLA +8.96% $SANA +7.30% $BEAM +6% while $CRBU declined -1.33%. - Yesterdays session was absolutely EPIC 🔥 with the rally sustained across these CRISPR names (except CRBU) signalling strong investor confidence in the sector's momentum. - @PrimeMedicine surged back $1bn mc bolstering its positioning after this stellar rebound. This milestone could be key as many institutional funds have minimum mc thresholds that previously restricted participation; now likely to pile in if they see" [X Link](https://x.com/3primeAnalytica/status/1974099746332545092) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-03T13:10Z 1270 followers, 2021 engagements "🚨 CRISPR News 🧬: AstraZeneca $AZN seals a $555m deal with Algen Biotechnologies for exclusive rights to AI-powered CRISPR therapies targeting immune disorders and cancer - underscoring the tech's accelerating potential to transform DD & spark investor interest. CRISPR's future keeps shining 🚀" [X Link](https://x.com/3primeAnalytica/status/1975225660206469311) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-06T15:44Z 1272 followers, 3518 engagements "Simeon is up $23m on the $CRSP bet he made in July.he's definitely sharing screenshots with his crew now. Too posh for that probably. Might start a tracker website 🙃" [X Link](https://x.com/3primeAnalytica/status/1976322679809462537) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-09T16:23Z 1272 followers, XXX engagements "$EDIT still a name I won't touch but I know many people are still in it likely just trading it.+184% YTD (went $X in Apr.).still not bad at all for those who traded it this year or who for some reason started investing in it this yr well done I guess. They presented good preclinic in vivo poc data for EDIT-401 last Thursday.mkt didn't care on the 9th definitely not on the 10th either.still progress.still won't touch" [X Link](https://x.com/3primeAnalytica/status/1977425295444500974) [@3primeAnalytica](/creator/x/3primeAnalytica) 2025-10-12T17:25Z 1271 followers, 1260 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@3primeAnalytica 3PrimeAnalytica
3PrimeAnalytica posts on X about $beam, $ntla, $crsp, $edit the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +492,918%
- X Year XXXXXXX +4,635%
Mentions: X #
- X Week XX -XX%
- X Month XX -XXXX%
- X Months XXX +16,400%
- X Year XXX +1,560%
Followers: XXXXX #
- X Week XXXXX +0.71%
- X Month XXXXX +9.90%
- X Months XXXXX +37%
- X Year XXXXX +37%
CreatorRank: undefined #
Social Influence #
Social category influence cryptocurrencies XXXXX% finance XXXXX% stocks XXXX% travel destinations XXXX% currencies XXXX% technology brands XXXX%
Social topic influence $beam #65, $ntla #37, $crsp #30, $edit 8.33%, $sana 5.56%, $prme 5.56%, $crbu 5.56%, london 2.78%, $rgnx 2.78%, stocks XXXX%
Top accounts mentioned or mentioned by @geneinvesting @tohjah7809 @crisprtx @vegan1 @biotech2k1 @jawnzilla @rolandoamoreno @vega_n1 @beamtx @astrazeneca @arkkdaily @matthughes13 @thechartlife @rainmaker1973 @primemedicine @intelliatx @oliverventure @neo8634
Top assets mentioned BEAM (BEAM) Intellia Therapeutics, Inc (NTLA) CRISPR Therapeutics AG (CRSP) GSK plc (GSK) Scholar Rock Holding Corporation Common Stock (SRRK) AstraZeneca PLC (AZN)
Top Social Posts #
Top posts by engagements in the last XX hours
"@TohJah7809 😁 green tea for the win matcha's so overpriced in London"
X Link @3primeAnalytica 2025-09-28T05:52Z 1270 followers, XX engagements
"Overnight looking good so far 👍🏼only bought a tiny bit of $BEAM last Friday though"
X Link @3primeAnalytica 2025-10-13T00:30Z 1270 followers, 1763 engagements
"FDA slapped Regenxbio with a 3-month delay on RGX-121 for Hunter syndrome - 'more data' is the favourite excuse 🙄. FDA delays continue to pile up = biotech dreams crushed again. $RGNX #FDAFail #Biotech #GeneTherapy 🔥"
X Link @3primeAnalytica 2025-08-20T10:51Z 1272 followers, XXX engagements
"after all these years 🥶 still being up on $NTLA $BEAM $CRSP after broad market jitters/liquidations I'm reading about this a.m. hits different"
X Link @3primeAnalytica 2025-10-11T16:10Z 1272 followers, 1249 engagements
".you really never know in this space tbh might start talking up next-gen editors too.i actually (and amusingly) mentioned this before crsp even mentioned SyNTase.it's been a while since the so called "first gens" have talked about these programs.btw wen $NTLA gene/dna writing tech from Rewrite Tx"
X Link @3primeAnalytica 2025-10-12T17:48Z 1272 followers, XXX engagements
"Here's your Morning CRISPR Brief ☕☀ Recap: gene editing stocks dipped 3-9% on Oct. 10th amid broader market weakness but fundamentals remain intact $CRSP -XXXX% $SANA -XXXX% $NTLA -XXXX% $BEAM -XXXX% $EDIT -XXXX% $PRME -XXXX% $CRBU -9.45%. Big Pharmas interest in CRISPR is heating up again 🔥 as evidenced by several partnerships and deals just last week. The unveiling of a next-gen platform like SyNTase and good poc data reflects steady momentum in the gene editing sector. Some highlights from last week: 1) Non-dilutive win for @BeamTx: $BMY acquired Orbital Therapeutics BEAM's RNA"
X Link @3primeAnalytica 2025-10-13T13:17Z 1272 followers, 2933 engagements
"$WVE released positive interim results for its RNA-editing therapy WVE-006 primarily developed under a partnership with $GSK which holds the global license and will assume full responsibility post-trial. The data indicate comparable total alpha-1 antitrypsin (AAT) levels to those reported in $BEAM's - XXX program with both achieving approximately 1112 M. However BEAM-302 demonstrates higher relative production of functional M-AAT (91% of total AAT) and a greater reduction in pathogenic Z-AAT (79%) compared to WVE-006 (64% M-AAT and XX% Z-AAT reduction). Waves data does seem to validate"
X Link @3primeAnalytica 2025-09-03T13:41Z 1270 followers, 1400 engagements
"$REGN's Chris Fenimore (CFO) and Ryan Crowe (SVP IR) participated in a fireside chat at Bernstein yesterday. 📈💊 Stock has declined XX% YTD. I think one of the cheapest underappreciated biopharma LT opptys out there. Comments on $SRRK CRL their own CRL Dupixent Eylea onco pipelline Complement & obesity plays. 📍On EYLEA HD Performance and Headwinds: - Strong sequential demand growth observed: X% in Q1 and XX% in Q2 driven by effective commercial execution and education efforts. - Offering enhanced dosing flex and durability compared to EYLEA 2mg. - Ongoing challenges: securing approvals for"
X Link @3primeAnalytica 2025-09-25T15:09Z 1272 followers, 2732 engagements
"Here's your Morning CRISPR Brief ☕☀ Recap: $PRME led gains +19.32% followed by $CRSP +10% $EDIT +9.58% $NTLA +8.96% $SANA +7.30% $BEAM +6% while $CRBU declined -1.33%. - Yesterdays session was absolutely EPIC 🔥 with the rally sustained across these CRISPR names (except CRBU) signalling strong investor confidence in the sector's momentum. - @PrimeMedicine surged back $1bn mc bolstering its positioning after this stellar rebound. This milestone could be key as many institutional funds have minimum mc thresholds that previously restricted participation; now likely to pile in if they see"
X Link @3primeAnalytica 2025-10-03T13:10Z 1270 followers, 2021 engagements
"🚨 CRISPR News 🧬: AstraZeneca $AZN seals a $555m deal with Algen Biotechnologies for exclusive rights to AI-powered CRISPR therapies targeting immune disorders and cancer - underscoring the tech's accelerating potential to transform DD & spark investor interest. CRISPR's future keeps shining 🚀"
X Link @3primeAnalytica 2025-10-06T15:44Z 1272 followers, 3518 engagements
"Simeon is up $23m on the $CRSP bet he made in July.he's definitely sharing screenshots with his crew now. Too posh for that probably. Might start a tracker website 🙃"
X Link @3primeAnalytica 2025-10-09T16:23Z 1272 followers, XXX engagements
"$EDIT still a name I won't touch but I know many people are still in it likely just trading it.+184% YTD (went $X in Apr.).still not bad at all for those who traded it this year or who for some reason started investing in it this yr well done I guess. They presented good preclinic in vivo poc data for EDIT-401 last Thursday.mkt didn't care on the 9th definitely not on the 10th either.still progress.still won't touch"
X Link @3primeAnalytica 2025-10-12T17:25Z 1271 followers, 1260 engagements